Aspirin Resistance in Obese and Elderly Patients with COVID-19?

We read with great interest the recent publication by McCullough et al proposing a comprehensive management strategy for ambulatory patients with coronavirus disease 2019 (COVID-19).1 The authors should be commended for proposing antiplatelet and antithrombotic therapy early in the disease.2 McCullough et al recommend 81 mg aspirin daily for high-risk, ambulatory patients with COVID-19.1 We suggest caution in relying on low-dose aspirin as chemoprophylaxis or treatment for immunothrombosis in COVID-19, especially in patients who are obese or elderly.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Letter Source Type: research